从基础-餐时胰岛素方案简化为基础胰岛素联合GLP-1RA固定比例或联合SGLT2抑制剂的可行性:BEYOND随机实用试验
BEYOND试验评估了在2型糖尿病血糖控制不佳者中,用基础胰岛素联合GLP-1RA或联合SGLT2抑制剂替代完整基础-餐时胰岛素方案的可行性。三组6个月HbA1c降幅相似且非劣效,联合方案组胰岛素剂量和低血糖比例更低,但联合组有脱落而基础-餐时组无脱落。
要点
- 基础胰岛素联合GLP-1RA固定比例或联合SGLT2抑制剂可替代基础-餐时方案,6个月HbA1c降幅非劣效。
- 联合方案组总胰岛素剂量下降而基础-餐时组增加,低血糖比例更低。
- 联合组存在脱落(固定组合12例、格列净组合9例),基础-餐时组无脱落。
核心结论
- 从基础-餐时胰岛素方案转换为每日一次基础胰岛素联合GLP-1RA固定比例或基础胰岛素加SGLT2抑制剂是可行且安全的,血糖控制相似,胰岛素剂量和每日注射次数更少,低血糖更少。
研究设计与样本
- 随机、实用试验,参与者按1:1:1随机分为基础-餐时胰岛素强化组(n=101)、基础胰岛素联合GLP-1RA固定比例组(n=102)和基础胰岛素联合SGLT2抑制剂组(n=102)。
- 主要疗效结局为6个月时HbA1c较基线的变化。
主要发现
- 三组基线特征相似,平均HbA1c为8.6%(70 mmol/mol)。
- 6个月时HbA1c降幅分别为-0.6±0.8%、-0.6±0.8%和-0.7±0.9%(均值±SD),非劣效P<0.001 vs 基础-餐时组。
- HbA1c≤7.5%的比例分别为34%、28%和27%(P=0.489)。
- 总胰岛素剂量在基础-餐时组增加(62单位/天),在固定组合组和格列净组合组分别减少(27单位/天和21单位/天)(P<0.01)。
- 低血糖比例分别为17.8%、7.8%和5.9%(P=0.015);脱落例数在固定组合组12例、格列净组合组9例、基础-餐时组0例。
临床怎么用
- 对于血糖控制不佳的2型糖尿病患者,可考虑将基础-餐时胰岛素方案简化为每日一次基础胰岛素联合GLP-1RA固定比例或联合SGLT2抑制剂,以减少胰岛素剂量、注射次数和低血糖风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: BEYOND trial evaluated the feasibility of either basal insulin plus glucagon-like peptide 1 receptor agonist (GLP-1RA) or basal insulin plus sodium-glucose cotransporter 2 inhibitor (SGLT2i) to replace a full basal-bolus insulin (BBI) regimen in participants with type 2 diabetes and inadequate glycemic control. RESEARCH DESIGN AND METHODS: Participants were randomized (1:1:1) to: 1) intensification of the BBI regimen (n = 101), 2) fixed ratio of basal insulin plus GLP-1RA (fixed-combo group; n = 102), and 3) combination of basal insulin plus SGLT2i (gliflo-combo group; n = 102). The primary efficacy outcome was change from baseline in HbA1c at 6 months. RESULTS: Baseline characteristics were similar among the three groups (mean HbA1c was 8.6% [70 mmol/mol]). At 6 months, patients experienced similar reduction in HbA1c level (-0.6 ± 0.8, -0.6 ± 0.8, and -0.7 ± 0.9%, mean ± SD, respectively; noninferiority P < 0.001 vs. BBI), and the proportion of patients with HbA1c ≤7.5% was also similar (34%, 28%, and 27%, respectively; P = 0.489). Total insulin dose increased in the BBI group (62 units/day) and decreased both in the fixed-combo and gliflo-combo groups (27 units/day and 21 units/day, respectively; P < 0.01). The proportion of patients with hypoglycemia was 17.8%, 7.8%, and 5.9%, respectively (P = 0.015). There were 12 dropouts in the fixed-combo group, 9 in the gliflo-combo group, and none in the BBI group. CONCLUSIONS: BEYOND provides evidence that it is possible and safe to switch from a BBI regimen to either a once-daily fixed-combo injection or once-daily gliflozin added to basal insulin, with similar glucose control, fewer insulin doses, fewer injections daily, and less hypoglycemia.
引用
- Giugliano D, Longo M, Caruso P, et al. Feasibility of Simplification From a Basal-Bolus Insulin Regimen to a Fixed-Ratio Formulation of Basal Insulin Plus a GLP-1RA or to Basal Insulin Plus an SGLT2 Inhibitor: BEYOND, a Randomized, Pragmatic Trial. Diabetes Care. 2021. PMID: 33883195. doi:10.2337/dc20-2623
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。